Sigilon Therapeutics, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutic treatments for a wide range of chronic diseases. Its program includes Rare Blood Disorders, Lysosomal Storage Diseases, and Endocrine and Other Chronic Diseases. The company was founded by Daniel G. Anderson, Robert S. Langer Jr., Jose Oberholzer, Arturo Vegas, and Omid Veiseh on May 14, 2015 and is headquartered in Cambridge, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Sigilon Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Sigilon Therapeutics Inc market cap is $56.49M.
What is the 52-week high for Sigilon Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Sigilon Therapeutics Inc 52 week high is $28.00 as of September 07, 2025.
What is the 52-week low for Sigilon Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Sigilon Therapeutics Inc 52 week low is $3.77 as of September 07, 2025.
What is Sigilon Therapeutics Inc stock price today?
Sigilon Therapeutics Inc stock price today is $22.47.
What was Sigilon Therapeutics Inc stock price yesterday?
Sigilon Therapeutics Inc stock price yesterday was $23.06.
What is the PE ratio of Sigilon Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Sigilon Therapeutics Inc’s P/E ratio is -1.86.
What is the Price-to-Book ratio of Sigilon Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Sigilon Therapeutics Inc P/B ratio is 2.0484.
What is Sigilon Therapeutics Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Sigilon Therapeutics Inc's EBITDA is -1.11.
What is the 50-day moving average of Sigilon Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Sigilon Therapeutics Inc 50-day moving average is $16.97.